The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 13 April 2026•Updated 13 April 2026•

1 min read

Genflow Biosciences Announces International Patent Publication to Strengthen IP Portfolio

Key Facts

1Genflow Biosciences PLC announced the publication of an international patent.

about 2 months ago

Version History

1 additional source confirmed this story

Version 1about 2 months ago

What changed: The update specifies the therapeutic focus on SIRT6 for muscular diseases, mentions the PCT filing, and identifies the company's secondary listings on the OTCQB and Frankfurt exchanges.

Genflow Biosciences PLC (GENF.L), which is also listed on the OTCQB (GENFF) and Frankfurt (WQ5) exchanges, has announced the formal publication of an international patent under the Patent Cooperation Treaty (PCT). This development marks a significant milestone as the patent protection for SIRT6 has been expanded to include the treatment of muscular diseases. The company confirmed that this announcement is classified as inside information under the UK Market Abuse Regulation (MAR), highlighting its regulatory importance. This publication is a critical component of the legal process to protect the company's biotechnological innovations and secure its market position globally. By formalizing these rights, Genflow Biosciences aims to solidify its competitive edge and ensure long-term value for its shareholders across multiple jurisdictions. Investors typically monitor these developments closely as they form the foundation for a biotechnology company's long-term valuation and commercial potential.